Elite Pharmaceuticals (OTCMKTS:ELTP) Issues Earnings Results

Elite Pharmaceuticals (OTCMKTS:ELTP) announced its quarterly earnings results on Thursday. The specialty pharmaceutical company reported ($0.01) EPS for the quarter, Zacks reports. Elite Pharmaceuticals had a negative net margin of 8.98% and a positive return on equity of 15.55%.

Elite Pharmaceuticals Trading Up 6.5 %

Shares of ELTP stock traded up $0.03 on Thursday, hitting $0.55. The stock had a trading volume of 1,739,250 shares, compared to its average volume of 798,234. The company’s 50 day moving average price is $0.52 and its 200-day moving average price is $0.44. Elite Pharmaceuticals has a 1 year low of $0.12 and a 1 year high of $0.75. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.52 and a quick ratio of 2.42. The firm has a market capitalization of $585.25 million, a P/E ratio of -54.78 and a beta of 0.27.

Elite Pharmaceuticals Company Profile

Elite Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals.